Dr. Eggebeen & Rituximab in Myositis (RIM) Study Group

Dermatomyositis

Inflammatory cells around and invading into muscle cells causing damage to skeletal muscle and weakness in patients.

After more than 5 years of meticulous planning and arduous execution Dr. Eggebeen and national colleagues have completed the multicenter "Rituximab in Myositis Study" the results have been published in the Nov 2 edition of Arthritis and Rheumatism. This is the first of many publications which will arise from this landmark clincal trial which evaluates the effects of the B-cell depleting monoclonal antibody rituximab on children and adults with polymyositis and dermatomyositis that was resistent to standard therapies.  Although no significant differences were detected between the treatment groups, 83% of refractory adult and juvenile myositis patients met the definition of improvement by the end of the trial. 

©2015 West Michigan Rheumatology, PLLC                1155 East Paris SE, Suite 100                              Grand Rapids, MI 49546                                               Voice 616.459.8088                                                       FAX 616.459.8312                                                www.mi-arthritis.com